Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Allergan's Avycaz gets Priority Review

In October, FDA accepted and granted Priority Review to an sNDA from Allergan plc (NYSE:AGN) for

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE